| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_838506d9bc9230544c21d5b963961e67
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_114e4423ec77cbc8dab9d0a98909704e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_95431414697e7cdd51319707233d43ff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_841a75a3585438c3567f9bd875c60467
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_893dfb7798e4ab91024e9e6f4d902350 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-1019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0008 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-10 |
| filingDate |
2007-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83d328acfdd49d45b68f4823c43cec5c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e0b3cefaca7c7b81efffd4bba3502e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e161a441682131695bde7f08472468d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9320eefa647a5d538ec2d2a018d2b11 |
| publicationDate |
2007-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2007116276-A2 |
| titleOfInvention |
Integrin binding rgd-lipopeptides with gene transfer activities |
| abstract |
The present invention provides synthesis of a novel series of cationic lipopeptides with integrin-binding RGD functionalities. The invention also provides high L27 (transformed Sl 80, mouse sarcoma cells) cell tropic gene transfer properties of these novel RGD-lipopeptides. Since L27 cell surface contains over expressed integrins, the present class of lipopeptides with integrin-binding RGD ligands are likely to find future applications in targeting anti-cancer genes/drugs to the endothelial cells of tumor vasculatures (possessing over expressed integrins). |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010163364-A |
| priorityDate |
2006-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |